Somerset, NJ, January 22, 2013 — Gregory T. Bleck, Ph.D., Research and Development Platform Director - Biologics for Catalent Pharma Solutions, will present “GPEx® Cell Line Engineering Case Studies using Multiple Mammalian Cell Lines” at PepTalk 2013.
Through case study examples, attendees will gain an understanding of how GPEx Cell Line Engineering has been used to insert genes into several different mammalian cell lines for biopharmaceutical production. The presentation will discuss the procedures completed, analysis of data, insights gained, and final conclusions that demonstrate how GPEx technology was used to generate mammalian cells with high yields and stability; helping to speed drugs to clinic.
Dr. Bleck has a broad background in Molecular Biology and gene expression with 12 year’s experience within the organization. Dr. Bleck holds a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and protein expression. Dr. Bleck has published more than 55 research papers and co-authored chapters in three books.
PepTalk 2013 – The Protein Science Week, will be held in Palm Springs, CA from January 21-25, 2013. Dr Bleck’s presentation will take place on January 25 within ‘pipeline 4’ of the conference in a segment entitled “Choosing, Designing and Optimizing Hosts and Platforms.” The conference is divided into pipelines with a focus on formulation, purification, biotherapeutics, expression and packaging. For more information on this event, please visit: www.chi-peptalk.com
To schedule an interview with the above mentioned presenter, during PepTalk 2013 or after, or to receive a copy of the presentation after the event, please contact Chris Halling at email@example.com
Click here for more information on Catalent’s GPEx technology.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™